Cartilage-targeted Exosome Gene Therapy for OA Pain Relief
Official title: Cartilage targeting exosomes for OA gene therapy and pain treatment
Funded at Northeastern University · NIH-11390414 · Data updated 2026-11-12
A new, non-viral gene-delivery approach uses engineered exosomes to deliver therapeutic genes directly to cartilage and help relieve pain in people with osteoarthritis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northeastern University NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | June 17, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $652,195 |
| NIH project number | 1R01AR086588-01A1 |
| Project ID | NIH-11390414 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with osteoarthritis or cartilage damage who have pain and are eligible for gene-delivery approaches or early-phase OA therapies.
✕Less likely to help
Patients without OA or those not eligible for intra-articular or gene-delivery approaches may not benefit.
What this research studies
This project uses surface-modified exosomes derived from mesenchymal stem cells to carry therapeutic genetic material into thick cartilage and deeper chondrocyte layers. By anchoring arginine-rich peptides to the exosome surface, the researchers aim to improve penetration through cartilage and within the joint to deliver IL-1RA mRNA and siRNA against NaV1.8, potentially promoting cartilage repair and reducing pain. The work combines advanced bioengineering with joint biology to create a targeted, non-immunogenic delivery system for OA. If successful, this could translate into a new therapeutic option for patients with OA who have cartilage loss and persistent pain.
Why it matters
Potential benefit: If successful, patients could receive a targeted, non-viral treatment that promotes cartilage repair and reduces OA pain.
How similar studies have gone: Similar exosome-based, non-viral delivery strategies have shown promise in preclinical cartilage repair and immunogenicity reduction, but human clinical translation is still emerging.
Where this research is happening
-
Northeastern University
Boston, United States Active
Researchers
- Principal investigator: Bajpayee, Ambika Goel — Northeastern University
- Study coordinator: Bajpayee, Ambika Goel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.